

We Claim,

1. A pharmaceutical composition for treatment or prevention of an inflammatory disease, comprising a lectin protein; wherein the lectin protein is recombinant and is derived from *Sclerotium rolfsii*; wherein the lectin protein comprises an amino acid sequence of SEQ ID NO. 2.
2. The pharmaceutical composition as claimed in claim 1, wherein the lectin protein is capable of a) inhibiting the secretion of inflammatory cytokines; and/or b) reducing C-reactive protein (CRP) levels in blood; and/or c) stimulating ACP activity and/or collagen levels.
3. The pharmaceutical composition as claimed in claim 1 or 2, wherein the inflammatory disease is a chronic inflammatory disease.
4. The pharmaceutical composition as claimed in claim 3, wherein the chronic inflammatory disease is psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), hepatitis, asthma, inflammatory bowel disease (including crohn's disease, colitis and irritable bowel syndrome (IBS)), temporal arteritis, atopic dermatitis, systemic lupus, multiple sclerosis or sarcoidosis.
5. The pharmaceutical composition as claimed in claim 3, wherein the chronic inflammatory disease is rheumatoid arthritis (RA).
6. The pharmaceutical composition as claimed in claim 1 or 2, wherein the inflammatory disease is acute inflammation.
7. The pharmaceutical composition as claimed in claim 6, wherein the acute inflammation is caused by an allergic reaction, an infection or trauma.
8. A pharmaceutical composition comprising a lectin protein and a pharmaceutically acceptable diluent or excipient for treatment or prevention of an inflammatory disease in a subject; wherein the lectin protein is recombinant and is derived from *Scelrotium rolfsii*; wherein the lectin comprises an amino acid sequence of SEQ ID NO. 2; wherein dose of the lectin protein is 1 to 50 mg/kg body weight of the subject.
9. Use of a lectin protein in the manufacture of a medicament for treatment or prevention of an inflammatory disease; wherein the lectin protein is recombinant and is derived from *Sclerotium rolfsii*; wherein the lectin protein comprises an amino acid sequence of SEQ ID NO. 2.
10. The use as claimed in claim 9, wherein the lectin protein is capable of a) inhibiting the secretion of inflammatory cytokines; and/or b) reducing C-reactive protein (CRP) levels in blood; and/or c) stimulating ACP activity and/or collagen levels.
11. The use as claimed in claim 9 or 10, wherein the inflammatory disease is a chronic inflammatory disease.
12. The use as claimed in claim 11, wherein the chronic inflammatory disease is psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), hepatitis, asthma, inflammatory bowel disease (including crohn's disease, colitis and irritable bowel syndrome (IBS)), temporal arteritis, atopic dermatitis, systemic lupus, multiple sclerosis or sarcoidosis.

13. The use as claimed in claim 11, wherein the chronic inflammatory disease is rheumatoid arthritis (RA).
14. The use as claimed in claim 9 or 10, wherein the inflammatory disease is acute inflammation.
15. The use as claimed in claim 14, wherein the acute inflammation is caused by an allergic reaction, an infection or trauma.